Quantum Biopharma (QNTM) Other Non Operating Income (2020 - 2026)
Quantum Biopharma recorded quarterly Other Non Operating Income of $7.0 million in Q1 2026, up 158.82% quarter-over-quarter from -$11.8 million in Q4 2025, and up 123.6% year-over-year from $3.1 million in Q1 2025.
Quantum Biopharma's Other Non Operating Income history runs 7 years deep, the most recent figure standing at $7.0 million for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 123.6% year-over-year to $7.0 million; the TTM figure through Mar 2026 stood at -$3.5 million (down 208.03% YoY), while the FY2025 annual figure was -$11.9 million, down 11498.54% from the prior year.
- Other Non Operating Income came in at $7.0 million for Q1 2026 at Quantum Biopharma, up from -$11.8 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $7.0 million in Q1 2026 to a low of -$11.8 million in Q4 2025.
- A 5-year average of -$42527.8 and a median of $135746.0 in 2024 frame the typical range for Other Non Operating Income.
- On a YoY basis, Other Non Operating Income climbed as much as 1690813.51% in 2025 and fell as far as 8809.96% in 2025.
- Quantum Biopharma's Other Non Operating Income stood at -$1.5 million in 2022, then jumped by 113.96% to $212256.0 in 2023, then sank by 36.05% to $135746.0 in 2024, then plunged by 8809.96% to -$11.8 million in 2025, then soared by 158.82% to $7.0 million in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $7.0 million, -$11.8 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.95 Mn |
| Dec 31, 2025 | -23.82 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 110,267.00 |
| Mar 31, 2025 | 3.11 Mn |
| Dec 31, 2024 | 99,327.00 |
| Sep 30, 2024 | 74.00 |
| Mar 31, 2024 | 17,476.00 |
| Dec 31, 2023 | 212,256.00 |
| Dec 31, 2022 | -1.52 Mn |
| Sep 30, 2022 | 789,905.00 |
| Jun 30, 2022 | 409,198.00 |
| Mar 31, 2022 | -200,056.00 |
| Jun 30, 2021 | -294,947.00 |
| Mar 31, 2021 | 556,556.00 |
| Sep 30, 2020 | -671,065.62 |
| Mar 31, 2020 | -473,206.71 |